• InxMed

  Participated · Series B · Mar 2022

  InxMed is a clinical-stage biotechnology company based in Nanjing that develops therapies targeting the stromal microenvironment to overcome solid tumor resistance and metastasis. Founded at the end of 2018 and led by CEO Dr. Zaiqi Wang, the company focuses particularly on addressing anti‑PD‑1/PD‑L1 treatment resistance. Its lead asset, IN10018, is a potent and highly selective ATP‑competitive FAK inhibitor for which InxMed holds exclusive global development and commercial rights. IN10018 received FDA fast track designation in August 2021 and a breakthrough designation from China’s NMPA for the treatment of platinum‑resistant ovarian cancer. InxMed plans to use the $15M raised in a Series B+ to accelerate ongoing clinical trials in the US and China, initiate pivotal trials in the second half year, advance additional stroma‑targeting programs into clinics, and strengthen R&D capabilities in Nanjing. The company has established partnerships with multinational pharmaceutical companies including Merck, Roche and Boehringer Ingelheim and intends to disclose more IN10018 data at ASCO in June 2022. InxMed Co., Ltd is a clinical-stage biotechnology company based in Nanjing, China, focused on therapies that target the stromal microenvironment and drug resistance in hard-to-treat solid tumors. Its lead asset, IN10018, is a potent, selective ATP-competitive focal adhesion kinase (FAK) small-molecule inhibitor with ongoing trials in NRAS mutant metastatic melanoma, platinum-resistant ovarian cancer, and triple-negative breast cancer. The U.S. Food and Drug Administration granted Fast Track designation to IN10018 for platinum-resistant ovarian cancer in August 2021 based on preliminary efficacy. The company says it will use the $50M Series B proceeds to accelerate IN10018 clinical trials in both the U.S. and China, including initiation of pivotal trials, and to advance additional stroma-targeting programs into the clinic this year. InxMed has built translational medicine and clinical development teams across Shanghai, Beijing, Nanjing, the United States, Canada, and Australia, and has partnerships with Merck, Roche, and Boehringer Ingelheim. The company is led by founder and CEO Dr. Zaiqi Wang and will strengthen R&D capabilities in Nanjing with the new funding. InxMed is a Nanjing-based biotech focused on developing FAK inhibitors. The company is advancing a program toward Phase I development of a FAK inhibitor. Nearly a year after securing its first IND approval, InxMed raised new capital to support clinical progress. The company completed a ¥130 million (about $19 million) Series A+ financing. Proceeds from the raise are intended to fund the Phase I FAK inhibitor program. Zaiqi Wang is named as CEO.

• Aleph Farms

  Led · Series B · Jul 2021

  Aleph Farms grows beef steaks from non‑genetically engineered cells isolated from a living cow, producing whole cuts without harming animals. The company released the world’s first cultivated steak in December 2018 and a cultivated ribeye in 2021. Co‑founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg, Aleph Farms is headquartered in Israel. Its global investor network includes L Catterton, DisruptAD (ADQ), BRF, Thai Union and Cargill, and it recently announced an investment from Leonardo DiCaprio, who joined its advisory board. They cite an independent Life Cycle Analysis projecting cultivated beef could reduce climate impact by 92%, air pollution by 93%, use 95% less land and 78% less water versus industrial beef production. Aleph Farms positions its product to deliver familiar meat qualities while eliminating antibiotics and reducing risks of pathogens through an automated, sterile manufacturing process. Aleph Farms grows beef steaks from non-genetically engineered cells isolated from a living cow, producing meat without harming animals and with a reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Technion. Aleph is based in Rehovot, Israel. It raised $105M in a Series B to scale up manufacturing and expand operations internationally ahead of an initial market launch planned for 2022. Near-term milestones include scaling up manufacturing, growing operations internationally, and expanding its product lines and technology platform. The company is working with regulatory agencies on its plans for market entry. Aleph Farms produces real meat cuts grown from cow cells and operates a slaughter-free process to make steaks in large, clean bio-farm facilities similar to dairy operations. Its non-GMO technology, co-developed with Professor Shulamit Levenberg of the Technion, isolates the cells responsible for muscle regeneration and grows them outside the animal to form the same muscle tissue typical of steaks. The company intends to use recent funding to accelerate product development and to transform its prototype into a commercial product. Aleph was co-founded by The Kitchen Hub and Didier Toubia, who serves as CEO. The company is based in Ashdod, Israel and has positioned its platform for scale-up in controlled bio-farm environments.

No current team members are available.